Silica (Orthosilicic Acid)

Silicon is the second most abundant element in the Earth’s crust, yet most of it is locked in insoluble rocks and minerals that the human body cannot access. The small fraction that is bioavailable — primarily as orthosilicic acid (OSA, Si(OH)4) in water and some plant foods — appears to play a genuine role in connective tissue health, bone mineralization, and collagen integrity. But the supplement market is flooded with silica products that contain mostly insoluble, non-bioavailable forms, making the distinction between effective and ineffective products critical.

The mechanism centers on connective tissue matrix formation. Silicon is thought to act as a cross-linking agent in collagen and glycosaminoglycan matrices, improving the structural integrity of bone, cartilage, skin, hair, and nails. Carlisle’s early animal studies showed that silicon deficiency produced skeletal abnormalities, and subsequent research demonstrated that silicon stimulates osteoblast activity and collagen matrix formation in bone. The collagen matrix serves as the organic scaffold upon which calcium phosphate mineralizes — without adequate matrix, mineralization is impaired regardless of calcium and vitamin D intake.

Spector’s 2008 trial in BMC Musculoskeletal Disorders is the pivotal clinical study. In a randomized, double-blind, placebo-controlled trial of 184 osteopenic women, choline-stabilized orthosilicic acid (ch-OSA) at 6 mg silicon daily significantly increased the bone formation marker PINP (procollagen type I N-terminal propeptide) compared to placebo after 12 months. A post-hoc subgroup analysis showed significant improvement in femoral neck BMD for the 6 mg dose in women with lower baseline bone density. This is not a blockbuster effect — BMD improvements were modest — but it is a real, statistically significant signal from a well-designed trial.

The epidemiological evidence is supportive. Jugdaohsingh’s 2004 analysis of the Framingham Offspring cohort (2,847 participants) found that higher dietary silicon intake was positively associated with hip bone mineral density in men and premenopausal women, with differences of up to 10% between the highest and lowest quintiles of intake. This association was not seen in postmenopausal women, suggesting that silicon’s bone benefits may be most relevant during periods of active bone formation.

The honest framing must address the bioavailability problem. Most silica supplements — including horsetail extract, colloidal silica, and silicon dioxide — provide silicon in forms that are poorly absorbed (<10% bioavailability). Only choline-stabilized orthosilicic acid (ch-OSA, marketed as BioSil) has been shown to achieve approximately 30% bioavailability and has clinical trial evidence. Generic “silica” or “horsetail” supplements may contain silicon that passes through the body unabsorbed.

Safety is generally good at supplemental doses. The tolerable upper intake level has not been established for silicon, but dietary intakes of 20–50 mg/day are common without adverse effects. The main safety concern is confusion with crystalline silica (quartz), which causes silicosis when inhaled — this is completely different from orthosilicic acid supplements and irrelevant to oral ingestion.

Practical guidance: If you want to try silicon for bone or connective tissue health, use only choline-stabilized orthosilicic acid (ch-OSA) at 6–12 mg elemental silicon daily. Take with food. Give it 3–6 months before assessing bone or skin benefits. Combine with collagen peptides, vitamin C, calcium, and vitamin D for synergistic connective tissue support. Avoid generic horsetail or colloidal silica products that lack bioavailability data. In India, ch-OSA is available from Himalayan Organics and NutriJa.